According to Sandoz, South Korea has approved 50 mcg/250 mcg and 50 mcg/500 mcg dosages of the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD. The marketing authorization is the first for AirFluSal Forspiro in Asia.
A number of European countries have approved the inhaler, including Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria. Sandoz has launched the DPI in Denmark and Germany.
Sandoz Head of Global Respiratory Franchise Jan-Torsten Tews commented, “We are pleased to receive the marketing authorization in South Korea for AirFluSal Forspiro. This is our first approval in Asia and outside Europe and a milestone in our strategy of bringing our innovative inhaler to more patients across the world.”
Read the Sandoz press release.
